SAN DIEGO, June 16, 2011 /PRNewswire/ -- Profil® Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, announced today the appointment of Dr. Andrew Krentz as Senior Director of Scientific Services. Dr. Krentz, who is currently a senior scientific consultant for Profil Institute, will take on his new position in October following his relocation from the UK to San Diego. In his new role he will oversee Profil Institute's scientific services department and its integrated, science-driven approach from clinical trial protocol design to the publication of metabolic studies.
"Dr. Krentz has achieved great renown in the US and internationally for his clinical research on the pathogenesis and treatment of diabetes and cardio-metabolic disorders," said Dr. Marcus Hompesch, Profil Institute President and CEO. "Because of our focused disease approach of diabetes and obesity and because we are privileged to have a scientific management team of world-renowned experts in these specific disease areas, the number of clinical trials we perform yearly has doubled since 2006. Dr. Krentz is an important addition to our scientific team and the caliber of his expertise is a perfect fit."
Dr. Krentz trained in metabolic medicine at leading academic institutions in the UK and US. After obtaining his MD thesis Metabolic Studies in Insulin Resistance from the University of Birmingham he expanded his research repertoire at the New Mexico School of Medicine in Albuquerque. He pursued his clinical academic career as Consultant Physician in Diabetes and Endocrinology at Southampton University Hospitals and Honorary Senior Lecturer at the University of Southampton before returning to the US to take up a British Heart Foundation International Research Fellowship at the University of California San Diego.
Dr. Krentz comes to Profil Institute from the Bedfordshire and Hertfordshire Postgraduate Medical School where he currently holds a position at Associate Professor level within the Institute of Diabetes for Older People (IDOP). Dr. Krentz's forthcoming appointment as Visiting Professor at the University of Bedfordshire will maintain his academic affiliation with IDOP.
Dr. Krentz's expertise in metabolic and vascular medicine is reflected by his membership of several prominent national and international scientific societies. In the UK he is a council member of the Lipids, Metabolism & Vascular Disease Section of the Royal Society of Medicine. He is an elected member of the British Hypertension Society and is accredited as a clinical specialist in hypertension by the European Society for Hypertension. He is also a member of the European Group for the study of Insulin Resistance and the Diabetes and Cardiovascular Disease Study Group of the European Association for the Study of Diabetes.
Dr. Krentz is the author of a number of well-received textbooks on diabetes and vascular medicine and has published more than 150 original articles, reviews, editorials, and book chapters. Currently he is an associate editor for Diabetic Medicine (the official journal of Diabetes UK) and has served on editorial boards of the British Journal of Diabetes & Vascular Disease; Diabetes & Vascular Disease Research; Diabetes, Obesity & Metabolism; Drugs; Drugs & Aging and Treatments in Endocrinology.
About Profil® Institute for Clinical Research, Inc.
Profil Institute is world-renowned as a Center of Excellence for diabetes and obesity early phase clinical research. The company's advances in early phase drug research and its specific focus on diabetes, obesity and cardio-metabolic diseases as it relates to the diabetic patient population have led Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials.
To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 140 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices. The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Dusseldorf, Columbia University, University of Michigan and Harvard University. For more information visit www.profilinstitute.com.